Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.
The weakly immunogenic murine P1A Ag is a useful experimental model for the development of new vaccination strategies that could potentially be used against human tumors. An i.m. DNA-based immunization procedure, consisting of three inoculations with the P1A-coding pBKCMV-P1A plasmid at 10-day intervals, resulted in CTL generation in all treated BALB/c mice. Surprisingly, gene gun skin bombardment with the pBKCMV-P1A vector did not induce CTL, nor was it protective against a lethal challenge with the syngeneic P1A-positive J558 tumor cell line. To speed up the immunization procedure, we pretreated the tibialis anterior muscles with cardiotoxin, which induces degeneration of myocytes while sparing immature satellite cells. The high muscle-regenerative activity observable after cardiotoxin inoculation was associated with infiltration of inflammatory cells and expression of proinflammatory cytokines. A single pBKCMV-P1A plasmid inoculation in cardiotoxin-treated BALB/c mice allowed for sustained expansion of P1A-specific CTL and the induction of strong lytic activity in <2 wk. Cardiotoxin adjuvanticity could not be replaced by another muscle-degenerating substance, such as bupivacaine, or by MF59, a Th1 response-promoting adjuvant. Although this vaccination schedule failed to induce tumor rejection in all immunized mice, the analysis of CD8 T cell responses at an individual mouse level disclosed that the cytotoxic activity of P1A-specific CTL was correlated to the antitumor efficacy. These results highlight the critical need to identify reliable, specific immunological parameters that may predict success or failure of an immune response against cancer.
Rosato
Antonio
A
Immunology Section, Department of Oncology and Surgical Sciences, University of Padua, Padua, Italy. antonio.rosato@unipd.it
Zoso
Alessia
A
Milan
Gabriella
G
Macino
Beatrice
B
Dalla Santa
Silvia
S
Tosello
Valeria
V
Di Carlo
Emma
E
Musiani
Piero
P
Whalen
Robert G
RG
Zanovello
Paola
P
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D019470:Biolistics; D019496:Cancer Vaccines / Q000235:genetics* / Q000276:immunology* / Q000627:therapeutic use; D002455:Cell Division / Q000276:immunology; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D004179:Cobra Cardiotoxin Proteins / Q000008:administration & dosage; D003602:Cytotoxicity, Immunologic; D004306:Dose-Response Relationship, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D005260:Female; D007113:Immunity, Innate / Q000235:genetics; D007115:Immunization Schedule; D007150:Immunohistochemistry; D007273:Injections, Intramuscular; D008213:Lymphocyte Activation / Q000235:genetics; D012515:Mast-Cell Sarcoma / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D018482:Muscle, Skeletal / Q000737:chemistry / Q000276:immunology / Q000473:pathology; D009368:Neoplasm Transplantation / Q000276:immunology; D010957:Plasmids; D015996:Survival Rate; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology*; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D004179:Cobra Cardiotoxin Proteins; D018984:Epitopes, T-Lymphocyte; D019444:Vaccines, DNA; C076546:tumor rejection antigen P815A, mouse